STAIR-HIV will randomize 30 virally suppressed adults to weekly alendronate or placebo, testing whether a familiar osteoporosis medicine can perturb persistent HIV reservoirs despite continued ART.
Read how Gilead’s once weekly oral Yeztugo filing could reshape HIV prevention, PrEP adherence and long acting therapy competition.
Gilead and Merck gain HIV momentum but face fresh oncology questions. See why this split pipeline update matters.
Gilead’s HIV engine is roaring again. But acquisition costs and oncology pressure leave investors asking how durable the reset really is.
AiCuris pritelivir shows superior lesion healing in HIV-associated refractory HSV. Explore what the Phase 3 data mean for regulation and practice.
ViiV Healthcare heads to CROI 2026 with ultra long-acting HIV data for VH4524184, VH4011499 and more. See what it changes next.